Allorion Therapeutics

Infographic highlighting Avenzo’s upcoming December ORION-1 clinical data presentation for AVZO-023, featuring a laboratory illustration and the investigational therapy’s focus on selective CDK4 inhibition and improved tolerability.

Pharma & Biotech

Avenzo Therapeutics to present first ORION-1 Phase 1 data for selective CDK4 inhibitor AVZO-023

by Pallavi Madhiraju
October 31, 2026
0 Comments

Avenzo will present first ORION-1 data for AVZO-023 in December, testing whether selective CDK4 inhibition offers a better tolerability profile.

Read More